Treatment Treatment period Route of administration Compound Concentration (mg/kg) 11β-HSD1 activities 11β-HSD2 activities Refs. Tissues Tissues Liver Kidney AM QF SAT VAT Liver Kidney AM QF SAT VAT Leanrats 24 hours IP GA 50 *↓ *↓ *↓ *↓ *↓ ↓ ↓ *↓ ↓ ↓ ↓ ↓ [38] 7days Oral GA 50 *↓ ↓ ↓ ↓ ↓ ↓ *↓ *↓ ↓ ↓ ↓ ↓ [43] 24 hours IP GE 50 *↓ ↓ ↓ ↓ ↓ ↓ **↑ **↑ ↓ ↓ ↓ ↓ [42] High-fat diet (animal-based) 28-days Oral GA 100 *↓ ↓ ↓ **↓ ↓ ↓ **↓ **↓ *↓ ↓ **↓ ↓ [53] High-fat diet (plant-based) 28-days Oral GA 100 *↓ ↓ ↓ ↓ ↓ ↓ *↓ ↓ ↓ ↓ ↓ ↓ [54] High-sucrosediet 28-days Oral GA 100 **↓ *↓ *↓ *↓ **↓ **↓ *↓ **↓ *↓ ↓ ↓ *↓ [39] High-fat+high- sucrose+stress 28-days Oral GA 100 ↓ *↓ ↑ ↑ ↓ ↑ *↓ ↓ Not available Not available ↑ ↓ [41] Adrenalectomized 28-days Oral GA 100 *↑ ↑ *↑ *↑ ↑ *↑ *↑ ↑ ↑ ↑ ↑ ↓ [40]

Table 2: 11β-hydroxysteroid dehydrogenase type 1 and 2 (11β -HSD1 and 2) activities in different tissues under different physiological conditions (IP- intraperitoneal injection; AM: Abdominal muscle; QF- quadriceps femoris; SAT- subcutaneous adipose tissues; VAT- visceral adipose tissues; * and ** indicate significant changes with p-value of 0.05 and 0.01 respectively).